• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
YANG Qian, WANG Xiaojian. Research progress of sphingosine kinase 1 inhibitors[J]. Journal of China Pharmaceutical University, 2021, 52(6): 759-768. DOI: 10.11665/j.issn.1000-5048.20210615
Citation: YANG Qian, WANG Xiaojian. Research progress of sphingosine kinase 1 inhibitors[J]. Journal of China Pharmaceutical University, 2021, 52(6): 759-768. DOI: 10.11665/j.issn.1000-5048.20210615
shu

Research progress of sphingosine kinase 1 inhibitors

  • 1.

    Patent Examination Cooperation (Beijing) Center of the Patent Office, China National Intellectual Property Administration, Beijing 100160

  • 2.

    State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100050, China

More Information
  • Received Date: June 02, 2021
  • Revised Date: November 04, 2021
    Graphical Abstract
    • Abstract
  • Sphingosine kinase 1 (SphK1) is an important protein that regulates the lipid microenvironment of cell membranes, and plays an important role in the dynamic equilibrium of ceramide, sphingosine and sphingosine-1-phosphate.The overexpression of SphK1 is closely related to the occurrence, development and migration of tumors as well as the generation of drug resistance.SphK1 inhibitors can induce apoptosis of various tumor cells and reverse drug resistance, which has a good prospect for drug development.In this article, the structural biology of SphK1, the structural types and structure-activity relationships of SphK1 inhibitors are reviewed.
    • FullText(HTML)
    • References (47)
  • [1]
    . Pharmacol Rev，2008，60（2）：181-195.
    [2]
    Milstien S，Spiegel S. Targeting sphingosine-1-phosphate：a novel avenue for cancer therapeutics［J］. Cancer Cell，2006，9（3）：148-150.
    [3]
    Pitson SM. Regulation of sphingosine kinase and sphingolipid signaling［J］. Trends Biochem Sci，2011，36（2）：97-107.
    [4]
    Cao H，Ren HH，Lin FY，et al. Research status of sphingosine kinase 1［J］. Chin J Clin Pharmacol，2019，35（15）：1706-1708.
    [5]
    Pchejetski D，Bohler T，Stebbing J，et al. Therapeutic potential of targeting sphingosine kinase 1 in prostate cancer［J］. Nat Rev Urol，2011，8（10）：569-678.
    [6]
    Jin J，Wang XJ，Zhou WQ，et al. Pharmacological activity of a novel selective S1P1 agonist（prodrug）Syl978［J］. J China Pharm Univ （中国药科大学学报），2014，45 （3）：358-361.
    [7]
    Benakanakere MR，Zhao J，Galicia JC，et al. Sphingosine kinase-1 is required for toll mediated beta-defensin 2 induction in human oral keratinocytes［J］. PLoS One，2010，5（7）：e11512.
    [8]
    Zhao Z，Ma J，Hu B，et al. SPHK1 promotes metastasis of thyroid carcinoma through activation of the S1P/S1PR3/Notch signaling pathway［J］. Exp Ther Med，2018，15（6）：5007-5016.
    [9]
    Argraves KM，Wilkerson BA，Argraves WS，et al. Sphingosine-1-phosphate signaling promotes critical migratory events in vasculogenesis［J］. J Biol Chem，2004，279（48）：50580-50590.
    [10]
    Olivera A，Kohama T，Edsall L，et al. Sphingosine kinase expression increases intracellular sphingosine-1-phosphate and promotes cell growth and survival［J］. J Cell Biol，1999，147（3）：545-558.
    [11]
    Xia P，Gamble JR，Wang L，et al. An oncogenic role of sphingosine kinase［J］. Curr Biol，2000，10（23）：1527-1530.
    [12]
    Lee OH，Kim YM，Lee YM，et al. Sphingosine 1-phosphate induces angiogenesis： its angiogenic action and signaling mechanism in human umbilical vein endothelial cells［J］. Biochem Biophys Res Commun，1999，264（3）：743-750.
    [13]
    Nava VE，Hobson JP，Murthy S，et al. Sphingosine kinase type 1 promotes estrogen-dependent tumorigenesis of breast cancer MCF-7 cells［J］. Exp Cell Res，2002，281（1）：115-127.
    [14]
    Min J，Stegner AL，Alexander H，et al. Overexpression of sphingosine-1-phosphate lyase or inhibition of sphingosine kinase in dictyostelium discoideum results in a selective increase in sensitivity to platinum-based chemotherapy drugs［J］. Eukaryot Cell，2004，3（3）：795-805.
    [15]
    Sauer L，Nunes J，Salunkhe V，et al. Sphingosine kinase 1 inhibition sensitizes hormone-resistant prostate cancer to docetaxel［J］. Int J Cancer，2009，125（11）：2728-2736.
    [16]
    Bonhoure E，Lauret A，Barnes DJ，et al. Sphingosine kinase-1 is a downstream regulator of imatinib-induced apoptosis in chronic myeloid leukemia cells［J］. Leukemia，2008，22（5）：971-979.
    [17]
    Nava VE，Cuvillier O，Edsall LC，et al. Sphingosine enhances apoptosis of radiation-resistant prostate cancer cells［J］. Cancer Res，2000，60（16）：4468-4474.
    [18]
    Dai SD，Satoru I，Yuki Y，et al. Sphingosine kinase 1 is upregulated with lysophosphatidic acid receptor 2 in human colorectal cancer［J］. World J Gastroenterol，2016，22（8）：2503-2511.
    [19]
    Cao M，Ji C，Zhou Y，et al. Sphingosine kinase inhibitors： a patent review［J］. Int J Mol Med，2018，41（5）：2450-2460.
    [20]
    Coward J，Ambrosini G，Musi E，et al. Safingol（L-threo-sphinganine） induces autophagy in solid tumor cells through inhibition of PKC and the PI3-kinase pathway［J］. Autophagy，2009，5（2）：184-193.
    [21]
    Igarashi Y，Hakomori S. Enzymatic synthesis of N，N-dimethyl-sphingosine： demonstration of the sphingosine：N-methyltransferase in mouse brain［J］. Biochem Biophys Res Commun，1989，164（3）：1411-1416.
    [22]
    De Jonghe S，Van Overmeire I，Poulton S，et al. Structure-activity relationship of short-chain sphingoid bases as inhibitors of sphingosine kinase［J］. Bioorg Med Chem Lett，1999，9（21）：3175-3180.
    [23]
    Xiang Y，Asmussen G，Booker M，et al. Discovery of novel sphingosine kinase 1 inhibitors［J］. Bioorg Med Chem Lett，2009，19（21）：6119-6121.
    [24]
    Xiang Y，Hirth B，Kane JL，et al. Discovery of novel sphingosine kinase-1 inhibitors：part 2［J］. Bioorg Med Chem Lett，2010，20（15）：4550-4554.
    [25]
    Baek D J，MacRitchie N，Pyne NJ，et al. Synthesis of selective inhibitors of sphingosine kinase 1［J］. Chem Commun，2013，49（21）：2136-2138.
    [26]
    Schnute ME，McReynolds MD，Kasten T，et al. Modulation of cellular S1P levels with a novel potent and specific inhibitor of sphingosine kinase-1［J］. Biochem J，2012，444（1）：79-88.
    [27]
    Papakyriakou A，Cencetti F，Puliti E，et al. Glycans meet sphingolipids： structure-based design of glycan containing analogues of a sphingosine kinase inhibitor［J］. ACS Med Chem Lett，2020，11（5）：913-920.
    [28]
    Zhang Y，Berka V，Song A，et al. Elevated sphingosine-1-phosphate promotes sickling and sickle cell disease progression［J］. J Clin Invest，2014，124（6）：2750-2761.
    [29]
    Foss FW，T.PMathews，Kharel Y，et al. Synthesis and biological evaluation of sphingosine kinase substrates as sphingosine-1-phosphate receptor prodrugs［J］. Bioorg Med Chem，2009，17（16）：6123-6136.
    [30]
    Raje MR，Knott K，Kharel Y，et al. Design，synthesis and biological activity of sphingosine kinase 2 selective inhibitors［J］. Bioorg Med Chem，2012，20（1）：183-194.
    [31]
    Patwardhan NN，Morris EA，Kharel Y，et al. Structure-activity relationship studies and in vivo activity of guanidine-based sphingosine kinase inhibitors： discovery of SphK1- and SphK2-selective inhibitors［J］. J Med Chem，2015，58（4）：1879-1899.
    [32]
    Congdon MD，Kharel Y，Brown AM，et al. Structure-activity relationship studies and molecular modeling of naphthalene-based sphingosine kinase 2 inhibitors［J］. ACS Med Chem Lett，2016，7（3）：229-234.
    [33]
    Sibley CD，Morris EA，Kharel Y，et al. Discovery of a small side cavity in sphingosine kinase 2 that enhances inhibitor potency and selectivity［J］. J Med Chem，2020，63（3）：1178-1198.
    [34]
    French KJ，Schrecengost RS，Lee BD，et al. Discovery and evaluation of inhibitors of human sphingosine kinase［J］. Cancer Res，2003，63（18）：5962-5969.
    [35]
    French KJ，Upson J J，Keller SN，et al. Antitumor activity of sphingosine kinase inhibitors［J］. J Pharmacol Exp Ther，2006，318（2）：596-603.
    [36]
    Loveridge C，Tonelli F，Leclercq T. The sphingosine kinase 1 inhibitor 2-（p-hydroxyanilino）-4-（p-chlorophenyl）thiazole induces proteasomal degradation of sphingosine kinase 1 in mammalian cells［J］. J Bio Chem，2010，285（50）：38841-38852.
    [37]
    Aurelio L，Scullino CV，Pitman MR，et al. From sphingosine kinase to dihydroceramide desaturase：a structure-activity relationship（SAR）study of the enzyme inhibitory and anticancer activity of 4-（（4-（4-chlorophenyl）thiazol-2-yl）amino）phenol（SKI-II）［J］. J Med Chem，2016，59（3）：965-984.
    [38]
    Gustin DJ，Li Y，Brown ML，et al. Structure guided design of a series of sphingosine kinase（SphK）inhibitors［J］. Bioorg Med Chem Lett，2013，23（16）：4608-4616.
    [39]
    French KJ，Yan Z，Maines LW，et al. Pharmacology and antitumor activity of ABC294640 a selective inhibitor of sphingosine kinase-2［J］. J Pharm Exp Ther，2010，333（1）：129-139.
    [40]
    Beljanski V，Knaak C，Yan Z，et al. Combined anticancer effects of sphingosine kinase inhibitors and sorafenib［J］. Invest New Drugs，2011，29（6）：1132-1142.
    [41]
    Gao P，Y.KPeterson，Smith RA，et al. Characterization of isoenzyme-selective inhibitors of human sphingosine kinases［J］. PLoS One，2012，7（9）：e44543.
    [42]
    Pitman MR，Powell JA，Coolen C，et al. A selective ATP-competitive sphingosine kinase inhibitor demonstrates anti-cancer properties［J］. Oncotarget，2015，6（9）：7065-7083.
    [43]
    Kono K，Tanaka M，Ogita T，et al. F-12509A：a new sphingosine kinase inhibitor produced by a discomycete［J］. J Antibiot （Tokyo），2000，53（5）：459-466.
    [44]
    Bonhoure E，Pchejetski D，Aouali N，et al. Overcoming MDR-associated chemoresistance in HL-60 acute myeloid leukemia cells by targeting sphingosine kinase-1［J］. Leukemia，2006，20（1）：95-102.
    [45]
    Kono K，Sugiura M，Kohama T. Inhibition of recombinant sphingosine kinases by novel inhibitors of microbial origin F-12509A and B-5354c［J］. J Antibiot（Tokyo），2002，55（1）：99-103.
    [46]
    Kono K，Tanaka M，Ono Y，et al. S-15183a and b new sphingosine kinase inhibitors produced by a fungus［J］. J Antibiot （Tokyo），2001，54（5）：415-420.
    [47]
    Yoshimitsu Y，Miyagaki J，Oishi S，et al. Synthesis of pachastrissamine（jaspine B）and its derivatives by the late-stage introduction of the C-2 alkyl side-chains using olefin cross metathesis［J］. Tetrahedron，2013，69（21）：4211-4220.
    • Related Articles

  • Related Articles

    [1]TAO Junjie, YANG Jie, WEN Xiaodong. Studies on the chemical constituents in the aerial parts of Paris polyphylla var. Yunnanensis[J]. Journal of China Pharmaceutical University, 2020, 51(4): 454-460. DOI: 10.11665/j.issn.1000-5048.20200410
    [2]WANG Xiaoying, WANG Xiaying, QIU Liangzhen, OUYANG Huizhi, XU Wei. Cytotoxicity and cellular uptake of paclitaxel-loaded carboxymethyl chitosan-rhein polymeric micelles in MCF-7 cells[J]. Journal of China Pharmaceutical University, 2020, 51(1): 33-37. DOI: 10.11665/j.issn.1000-5048.20200106
    [3]CHENG Weihua, WANG Wenqian, SHANG Hai, ZHANG Hongwu, GUO Qiang, CHEN Hong, ZOU Zhongmei. Synthesis and cytotoxicity study of cembrane triazole derivatives[J]. Journal of China Pharmaceutical University, 2018, 49(1): 56-63. DOI: 10.11665/j.issn.1000-5048.20180108
    [4]TANG Yong, LIAO Shengrong, LI Jinsheng, LIU Yonghong. Design, synthesis and cytotoxic activities of fluorine-containing 2, 5-diketopiperazine derivatives[J]. Journal of China Pharmaceutical University, 2016, 47(4): 412-421. DOI: 10.11665/j.issn.1000-5048.20160405
    [5]SUN Hao, YANG Jiapei, MAO Yong, WANG Dandan, YU Feng. Involvement of Fas-dependent pathway in rhein-induced apoptosis of HK-2 cells[J]. Journal of China Pharmaceutical University, 2015, 46(4): 469-475. DOI: 10.11665/j.issn.1000-5048.20150414
    [6]WU Mingming, FANG Lei, GOU Shaohua, CHEN Li. 以2-甲基-2-取代苯氧基丙酸为离去基团的铂(Ⅱ)配合物的合成、表征及细胞毒活性[J]. Journal of China Pharmaceutical University, 2013, 44(4): 303-306. DOI: 10.11665/j.issn.1000-5048.20130403
    [7]FEI Jia, SUN Min-jie, PING Qi-neng, ZHANG Can. Preparation,characterization and safety evaluation for N-octyl-N-quaternary ammonium chitosan/CMCNa composite micelles[J]. Journal of China Pharmaceutical University, 2012, 43(4): 318-324.
    [8]SHEN Yan, LI Qian, FAN Da, LI Rui-jun, TU Jia-sheng. Influencing factors of hydrophobic modified hyaluronic acid-based cationic micelles and cell targeting in siRNA transfection[J]. Journal of China Pharmaceutical University, 2012, 43(2): 124-129.
    [9]GUO Zhong, ZHAO Jin, MA Jian-xiu, FU Si-wu. Effects of toxin A from Clostridium difficile on SMMC-7721 cells proliferation and apoptosis[J]. Journal of China Pharmaceutical University, 2009, 40(3): 250-253.
    [10]Structure-Cytotoxic Activity Relationships of Diterpenoid Tanshinones from Salvias[J]. Journal of China Pharmaceutical University, 2002, (1): 8-14.

Catalog

    Get Citation
    PDF
    XML
    Article views PDF downloads Cited by()
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：365762

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return